Literature DB >> 2278872

ACE inhibitors for the treatment of myocardial ischemia?

C Linder1, G Heusch.   

Abstract

Apart from their established use in the treatment of hypertension and heart failure, ACE inhibitors have been suggested to exert anti-ischemic effects. This article reviews the mechanisms of systemic and intracardiac angiotensin formation, as well as its interaction with the bradykinin, the prostaglandin, and the sympathetic nervous system. While high doses of angiotensin can precipitate myocardial ischemia. experimental data on a potential beneficial effect of ACE inhibitors on ischemic myocardial blood flow and function are inconsistent and controversial. Pooling the few available clinical data, several ACE inhibitors may attenuate myocardial ischemia at rest and during exercise. However, a significant fraction of patients does not benefit or even deteriorates. Recent experimental studies suggest a beneficial role of ACE inhibitors in attenuating reperfusion arrhythmias and postinfarction left ventricular remodeling. Unless the mechanisms and determinants of potential anti-ischemic actions of ACE inhibitors can be better defined, their use for treatment of myocardial ischemia cannot be recommended at present.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2278872     DOI: 10.1007/bf02018265

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  90 in total

1.  Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498.

Authors:  W H van Gilst; P A de Graeff; H Wesseling; C D de Langen
Journal:  J Cardiovasc Pharmacol       Date:  1986 Jul-Aug       Impact factor: 3.105

2.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction.

Authors:  M A Pfeffer; G A Lamas; D E Vaughan; A F Parisi; E Braunwald
Journal:  N Engl J Med       Date:  1988-07-14       Impact factor: 91.245

3.  Evidence for the existence of renin in the heart.

Authors:  V J Dzau; R N Re
Journal:  Circulation       Date:  1987-01       Impact factor: 29.690

4.  Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction.

Authors:  N Sharpe; J Murphy; H Smith; S Hannan
Journal:  Lancet       Date:  1988-02-06       Impact factor: 79.321

5.  Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor.

Authors:  G Ertl; R A Kloner; R W Alexander; E Braunwald
Journal:  Circulation       Date:  1982-01       Impact factor: 29.690

6.  The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina.

Authors:  J Simon; R Gibbs; P A Crean; L Mockus; C Wright; G C Sutton; K M Fox
Journal:  Br Heart J       Date:  1989-08

7.  The effect of captopril on the coronary circulation and myocardial metabolism of patients with coronary artery disease.

Authors:  B Mettauer; J L Rouleau; P Daly
Journal:  Postgrad Med J       Date:  1986       Impact factor: 2.401

8.  Interactions between coronary occlusion and the renin-angiotensin system in the dog.

Authors:  G Ertl; R W Alexander; R A Kloner
Journal:  Basic Res Cardiol       Date:  1983 Sep-Oct       Impact factor: 17.165

Review 9.  Intracardiac generation of angiotensin and its physiologic role.

Authors:  K Lindpaintner; M Jin; M J Wilhelm; F Suzuki; W Linz; B A Schoelkens; D Ganten
Journal:  Circulation       Date:  1988-06       Impact factor: 29.690

10.  Influence of local converting enzyme inhibition on angiotensin and bradykinin effects in ischemic rat hearts.

Authors:  W Linz; B A Schölkens
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

View more
  1 in total

1.  Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs.

Authors:  V Richard; B Ghaleh; A Berdeaux; J F Giudicelli
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.